Altamira Therapeutics has reported additional efficacy outcomes from its Bentrio clinical trial in seasonal allergic rhinitis. The NASAR clinical trial demonstrated the efficacy and tolerability of Bentrio nasal spray in treating seasonal allergic rhinitis, meeting both primary and secondary efficacy endpoints. The treatment also showed a statistically significant improvement in health-related quality of life secondary efficacy endpoint. The efficacy was demonstrated from the first day of the 2-week treatment period and across allergy symptoms and functional problems. Bentrio treatment was associated with a reduced need for relief medication.